$SGP

SpyGlass Pharma (SGP) presented at Citigroup’s Biopharma Summit, outlining plans for its BIM-IOL drug-device platform. The company reported strong clinical data, with 95% of patients free of additional glaucoma therapy at three years in early trials. SpyGlass has $234 million in cash, expects Phase III trial completion in 2028, and aims for a 2029 launch. The company targets a market of 200,000 annual cataract procedures in the U.S. with glaucoma.

SpyGlass Pharma Inc. (Nasdaq: SGP) has moved to a larger headquarters in Irvine, accommodating up to 150 employees. The biopharmaceutical company, which went public in February, is focused on drug delivery solutions for chronic eye conditions. It is currently conducting Phase 3 trials for its lead product, the BIM-IOL system, with a target launch in 2029. The company's stock traded at $28.99 with a $970 million market cap, up 77% since its IPO. SpyGlass has also secured a new AMA Category III co

The article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. •

Manila Electric Co. (Meralco) said it will join discussions on proposed amendments to the Electric Power Industry Reform Act (EPIRA) that could remove system loss charges from electricity bills. Meralco warned reforms should preserve distribution utility investment capacity. System loss is about 5% of bills in Meralco’s area. Meralco shares fell 4.66% to P562; SGP fell 0.36% to P28.

Australia’s ASX 200 (XJO) closed at 8,947.8, up 0.61%, a six-week high, after RBA Governor Michele Bullock signaled housing and labour markets have softened more than expected, easing August rate hike fears. The 10-year yield fell 5.2 bps. Consumer, tech and financials rose; gold, copper and lithium stocks fell.

SpyGlass Pharma Inc. appointed Shannon Treviño as general counsel, the company said. Treviño previously served as general counsel and corporate secretary at Inari Medical, acquired by Stryker for $4.9 billion, and held earlier legal and academic roles. SpyGlass CEO Patrick Mooney said she will support the company’s growth. Shares rose 2.7% to $18.93.

Master Builders Australia forecasts Australia will miss its target of 1.2 million new homes by July 2029, with a shortfall rising to 180,200 homes (from 160,000 earlier). It also says 180,500 homes started in 2024-25, about 60,000 below the Accord’s 240,000 goal. The article highlights ASX names James Hardie, Stockland and Mirvac as potential beneficiaries.

SpyGlass Pharma (Nasdaq: SGP) announced its executive management will participate in three upcoming investor conferences focused on healthcare and ophthalmology in May and June 2026. These events include the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will deliver corporate presentations or engage in fireside chats, with webcasts and replays available on its investor relations website.

SpyGlass Pharma Inc. has secured a new add-on Category III CPT Code for its intraocular lens (IOL) platform, which delivers glaucoma medication for up to three years. The Aliso Viejo-based company is currently in Phase 3 trials and aims for FDA submission by 2028 and commercial launch in 2029. This new billing code is expected to support the commercial model for their novel technology combining glaucoma and cataract treatment.